400 related articles for article (PubMed ID: 28802714)
21. Pharmacophore modelling as a virtual screening tool for the discovery of small molecule protein-protein interaction inhibitors.
Voet A; Zhang KY
Curr Pharm Des; 2012; 18(30):4586-98. PubMed ID: 22650262
[TBL] [Abstract][Full Text] [Related]
22. Hotspot Identification and Drug Design of Protein-Protein Interaction Modulators Using the Fragment Molecular Orbital Method.
Monteleone S; Fedorov DG; Townsend-Nicholson A; Southey M; Bodkin M; Heifetz A
J Chem Inf Model; 2022 Aug; 62(16):3784-3799. PubMed ID: 35939049
[TBL] [Abstract][Full Text] [Related]
23. Rational modulator design by exploitation of protein-protein complex structures.
Wichapong K; Poelman H; Ercig B; Hrdinova J; Liu X; Lutgens E; Nicolaes GA
Future Med Chem; 2019 May; 11(9):1015-1033. PubMed ID: 31141413
[TBL] [Abstract][Full Text] [Related]
24. MultiBacMam Bimolecular Fluorescence Complementation (BiFC) tool-kit identifies new small-molecule inhibitors of the CDK5-p25 protein-protein interaction (PPI).
Bellón-Echeverría I; Carralot JP; Del Rosario AA; Kueng S; Mauser H; Schmid G; Thoma R; Berger I
Sci Rep; 2018 Mar; 8(1):5083. PubMed ID: 29572554
[TBL] [Abstract][Full Text] [Related]
25. In silico design of low molecular weight protein-protein interaction inhibitors: Overall concept and recent advances.
Kuenemann MA; Sperandio O; Labbé CM; Lagorce D; Miteva MA; Villoutreix BO
Prog Biophys Mol Biol; 2015 Oct; 119(1):20-32. PubMed ID: 25748546
[TBL] [Abstract][Full Text] [Related]
26. Exhaustive Repertoire of Druggable Cavities at Protein-Protein Interfaces of Known Three-Dimensional Structure.
Da Silva F; Bret G; Teixeira L; Gonzalez CF; Rognan D
J Med Chem; 2019 Nov; 62(21):9732-9742. PubMed ID: 31603323
[TBL] [Abstract][Full Text] [Related]
27. Glutamine Synthetase Drugability beyond Its Active Site: Exploring Oligomerization Interfaces and Pockets.
Moreira C; Ramos MJ; Fernandes PA
Molecules; 2016 Aug; 21(8):. PubMed ID: 27509490
[TBL] [Abstract][Full Text] [Related]
28. Computational approaches for the design of modulators targeting protein-protein interactions.
Rehman AU; Khurshid B; Ali Y; Rasheed S; Wadood A; Ng HL; Chen HF; Wei Z; Luo R; Zhang J
Expert Opin Drug Discov; 2023 Mar; 18(3):315-333. PubMed ID: 36715303
[TBL] [Abstract][Full Text] [Related]
29. Small-molecule protein-protein interaction inhibitors: therapeutic potential in light of molecular size, chemical space, and ligand binding efficiency considerations.
Buchwald P
IUBMB Life; 2010 Oct; 62(10):724-31. PubMed ID: 20979208
[TBL] [Abstract][Full Text] [Related]
30. Computational Screening and Design for Compounds that Disrupt Protein-protein Interactions.
Johnson DK; Karanicolas J
Curr Top Med Chem; 2017; 17(23):2703-2714. PubMed ID: 28482793
[TBL] [Abstract][Full Text] [Related]
31. Discovery of a B-Cell Lymphoma 6 Protein-Protein Interaction Inhibitor by a Biophysics-Driven Fragment-Based Approach.
Kamada Y; Sakai N; Sogabe S; Ida K; Oki H; Sakamoto K; Lane W; Snell G; Iida M; Imaeda Y; Sakamoto J; Matsui J
J Med Chem; 2017 May; 60(10):4358-4368. PubMed ID: 28471657
[TBL] [Abstract][Full Text] [Related]
32. Dr. PIAS 2.0: an update of a database of predicted druggable protein-protein interactions.
Sugaya N; Kanai S; Furuya T
Database (Oxford); 2012; 2012():bas034. PubMed ID: 23060433
[TBL] [Abstract][Full Text] [Related]
33. State-of-the-art strategies for targeting protein-protein interactions by small-molecule inhibitors.
Sheng C; Dong G; Miao Z; Zhang W; Wang W
Chem Soc Rev; 2015 Nov; 44(22):8238-59. PubMed ID: 26248294
[TBL] [Abstract][Full Text] [Related]
34. A leap into the chemical space of protein-protein interaction inhibitors.
Villoutreix BO; Labbé CM; Lagorce D; Laconde G; Sperandio O
Curr Pharm Des; 2012; 18(30):4648-67. PubMed ID: 22650260
[TBL] [Abstract][Full Text] [Related]
35. Chemical Space Overlap with Critical Protein-Protein Interface Residues in Commercial and Specialized Small-Molecule Libraries.
Si Y; Xu D; Bum-Erdene K; Ghozayel MK; Yang B; Clemons PA; Meroueh SO
ChemMedChem; 2019 Jan; 14(1):119-131. PubMed ID: 30548204
[TBL] [Abstract][Full Text] [Related]
36. Targeting RNA structures in diseases with small molecules.
Shao Y; Zhang QC
Essays Biochem; 2020 Dec; 64(6):955-966. PubMed ID: 33078198
[TBL] [Abstract][Full Text] [Related]
37. Modulating protein-protein interactions: from structural determinants of binding to druggability prediction to application.
Metz A; Ciglia E; Gohlke H
Curr Pharm Des; 2012; 18(30):4630-47. PubMed ID: 22650257
[TBL] [Abstract][Full Text] [Related]
38. Synthesis and screening of small-molecule α-helix mimetic libraries targeting protein-protein interactions.
Moon H; Lim HS
Curr Opin Chem Biol; 2015 Feb; 24():38-47. PubMed ID: 25461722
[TBL] [Abstract][Full Text] [Related]
39. Identification of novel EED-EZH2 PPI inhibitors using an in silico fragment mapping method.
Misawa K; Yamaotsu N; Hirono S
J Comput Aided Mol Des; 2021 May; 35(5):601-611. PubMed ID: 33635506
[TBL] [Abstract][Full Text] [Related]
40. Biophysical and computational fragment-based approaches to targeting protein-protein interactions: applications in structure-guided drug discovery.
Winter A; Higueruelo AP; Marsh M; Sigurdardottir A; Pitt WR; Blundell TL
Q Rev Biophys; 2012 Nov; 45(4):383-426. PubMed ID: 22971516
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
